Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on June 15, 2016, primarily detailing the outcomes of their annual shareholder meeting held on June 14, 2016. The key event was the election of four directors to the board: Joshua Boger, Terrence C. Kearney, Yuchun Lee, and Elaine S. Ullian, all elected until the 2019 annual meeting. Notably, Joshua Boger's election involved a procedural resignation and re-appointment to balance the classes of directors, as previously disclosed. In addition to director elections, shareholders ratified the appointment of Ernst & Young LLP as the independent auditor for fiscal year 2016 and approved, on an advisory basis, the executive compensation program. Several shareholder proposals were voted upon, with the proposal to declassify the board receiving majority support. However, proposals concerning the limitation of equity award acceleration upon change of control, mandatory equity retention by executives, and a sustainability report were not approved.
Key Highlights
- 1Four directors (Joshua Boger, Terrence C. Kearney, Yuchun Lee, Elaine S. Ullian) were elected to the board for terms expiring in 2019.
- 2Joshua Boger's directorship involved a resignation and re-appointment to maintain board class balance, as pre-disclosed.
- 3Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016.
- 4An advisory vote on the compensation program for named executive officers was approved.
- 5A shareholder proposal requesting the declassification of the board of directors was approved.
- 6Shareholder proposals regarding limiting equity acceleration upon change of control, mandatory equity retention for executives, and a sustainability report were not approved.